Discreet Packing Anti-Estrogen Powder Faslodex CAS: 129453-6

Discreet Packing Anti-Estrogen Powder Faslodex CAS: 129453-61-8

Email:[email protected]
Skype:live:kathelin_4
WhatsApp:+86-188 7222 0706

 Formestane description
Fulvestrant Acetate (trade name Faslodex, by Astra Zeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is a completeestrogen receptor antagonist with no agonist effects, which in addition, accelerates the proteasomal degradation of the estrogen receptor. The drug has poor oral bioavailability, and is administered monthly via intramuscular injection.

Formestane basic info.
Fulvestrant (Steroids)
CAS:129453-61-8
Synonyms: FASLODEX
Chemical Name:(7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol
Molecular Fomular:C32H47F5O3S
Molecular Weight:606.77
Density:1.201 g/cm3
Melting Point:104-106℃
Boiling Point:674.8 °C at 760 mmHg
Appearance:white powder
Usage:Antineoplastic (hormonal)
Storage:2-8°C

 Applications:
Fulvestrant Acetate is a selective estrogen receptor degrader (SERD). It is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.

Fulvestrant Acetate provides effective second-line therapy in metastatic or locally advanced breast cancer for postmenopausal women who relapse or progress after previous endocrine therapy.

Four clinical trials in this setting showed similar efficacy to the other hormonal agents (aromatase inhibitors and tamoxifen) with good tolerability profile. Fulvestrant had a lower incidence of joint disorders.

A Phase 2 clinical trial, sponsored by Atossa Genetics, is being conducted by Dr. Sheldon Feldman, President of the The American Society of Breast Surgeons, at Columbia University Breast Center in New York City on the use of Fulvestrant Acetate administered through the microcatheter into the lactiferous duct as neoadjuvant treatment forductal carcinoma in situ and invasive breast cancer.